This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Enzo Life Sciences
other brands :
Stressgen, BioMol, Alexis Corporation, Assay Designs, Alexis
product type :
antibody
product name :
LAG-3 (human) monoclonal antibody (17B4) (biotin conjugate)
catalog :
ALX-804-806B-C100
quantity :
100 µg
clonality :
monoclonal
host :
mouse
conjugate :
biotin
clone name :
17B4

The same clone is also sold as:
reactivity :
human
application :
western blot, ELISA
citations: 19
Reference
Seifert A, Zeng S, Zhang J, Kim T, Cohen N, Beckman M, et al. PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors. Clin Cancer Res. 2017;23:454-465 pubmed publisher
Gulati N, Suárez Fariñas M, Correa Da Rosa J, Krueger J. Psoriasis is characterized by deficient negative immune regulation compared to transient delayed-type hypersensitivity reactions. F1000Res. 2015;4:149 pubmed publisher
Boer M, Prins C, van Meijgaarden K, van Dissel J, Ottenhoff T, Joosten S. Mycobacterium bovis BCG Vaccination Induces Divergent Proinflammatory or Regulatory T Cell Responses in Adults. Clin Vaccine Immunol. 2015;22:778-88 pubmed publisher
Juno J, Stalker A, Waruk J, Oyugi J, Kimani M, Plummer F, et al. Elevated expression of LAG-3, but not PD-1, is associated with impaired iNKT cytokine production during chronic HIV-1 infection and treatment. Retrovirology. 2015;12:17 pubmed publisher
Severson J, Serracino H, Mateescu V, Raeburn C, McIntyre R, Sams S, et al. PD-1+Tim-3+ CD8+ T Lymphocytes Display Varied Degrees of Functional Exhaustion in Patients with Regionally Metastatic Differentiated Thyroid Cancer. Cancer Immunol Res. 2015;3:620-30 pubmed publisher
Hatano R, Ohnuma K, Otsuka H, Komiya E, Taki I, Iwata S, et al. CD26-mediated induction of EGR2 and IL-10 as potential regulatory mechanism for CD26 costimulatory pathway. J Immunol. 2015;194:960-72 pubmed publisher
Juno J, Lajoie J, Stalker A, Oyugi J, Kimani M, Kimani J, et al. Enrichment of LAG-3, but not PD-1, on double negative T cells at the female genital tract. Am J Reprod Immunol. 2014;72:534-40 pubmed publisher
Tan A, Hoang L, Chin D, Rasmussen E, Lopatin U, Hart S, et al. Reduction of HBV replication prolongs the early immunological response to IFN? therapy. J Hepatol. 2014;60:54-61 pubmed publisher
Sumitomo S, Fujio K, Okamura T, Morita K, Ishigaki K, Suzukawa K, et al. Transcription factor early growth response 3 is associated with the TGF-?1 expression and the regulatory activity of CD4-positive T cells in vivo. J Immunol. 2013;191:2351-9 pubmed publisher
Radvanyi L, Bernatchez C, Zhang M, Fox P, Miller P, Chacon J, et al. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res. 2012;18:6758-70 pubmed publisher
Casati C, Camisaschi C, Novellino L, Mazzocchi A, Triebel F, Rivoltini L, et al. Human lymphocyte activation gene-3 molecules expressed by activated T cells deliver costimulation signal for dendritic cell activation. J Immunol. 2008;180:3782-8 pubmed
Triebel F, Hacene K, Pichon M. A soluble lymphocyte activation gene-3 (sLAG-3) protein as a prognostic factor in human breast cancer expressing estrogen or progesterone receptors. Cancer Lett. 2006;235:147-53 pubmed
Macon Lemaitre L, Triebel F. The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells. Immunology. 2005;115:170-8 pubmed
Di Carlo E, Cappello P, Sorrentino C, D Antuono T, Pellicciotta A, Giovarelli M, et al. Immunological mechanisms elicited at the tumour site by lymphocyte activation gene-3 (LAG-3) versus IL-12: sharing a common Th1 anti-tumour immune pathway. J Pathol. 2005;205:82-91 pubmed
Demeure C, Wolfers J, Martin Garcia N, Gaulard P, Triebel F. T Lymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3): role of LAG-3/MHC class II interactions in cell-cell contacts. Eur J Cancer. 2001;37:1709-18 pubmed
Hannier S, Tournier M, Bismuth G, Triebel F. CD3/TCR complex-associated lymphocyte activation gene-3 molecules inhibit CD3/TCR signaling. J Immunol. 1998;161:4058-65 pubmed
Huard B, Mastrangeli R, Prigent P, Bruniquel D, Donini S, el Tayar N, et al. Characterization of the major histocompatibility complex class II binding site on LAG-3 protein. Proc Natl Acad Sci U S A. 1997;94:5744-9 pubmed
Huard B, Gaulard P, Faure F, Hercend T, Triebel F. Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand. Immunogenetics. 1994;39:213-7 pubmed
Baixeras E, Huard B, Miossec C, Jitsukawa S, Martin M, Hercend T, et al. Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens. J Exp Med. 1992;176:327-37 pubmed
product information
Product ID :
ALX-804-806B
Catalog Number :
ALX-804-806B-C100
Product Name :
LAG-3 (human) monoclonal antibody (17B4) (biotin conjugate)
Host species :
Mouse
Clonality :
Monoclonal
Conjugation :
Biotin
Product Type :
Antibody
Size :
100 µg
list of Pubmed id :
18322184, 15946792, 15885122, 15586367, 11527700, 9780176, 9159144, 7506235, 1380059
Clone :
17B4
Isotype :
IgG1
SPECIES REACTIVITY :
Human
Background :
The lymphocyte activation gene-3 (LAG-3, CD223), a member of the immunoglobulin superfamily (IgSF) related to CD4, binds to the major histocompatibility complex (MHC) class II molecules but with higher affinity than CD4. Several alternative mRNA splice-variants of human LAG-3 have been described, two of them encoding potential secreted forms: LAG-3V1 (i.e. the D1-D2 domains of the protein, 36 kDa) and LAG-3V3 (D1-D3, 52 kDa). The longer form was detected by ELISA in the serum of healthy individuals as well as of tuberculosis patients with a favorable outcome. LAG-3 expression by T cell clones correlated with IFN-γ production, and hence soluble LAG-3 has been suggested as a serological marker of Th1 responses.
ALTnames :
Lymphocyte activation gene-3, FDC protein, CD223
Immunogen :
Synthetic peptide corresponding to 30 aa (GPPAAAPGHPLAPGPHPAAPSSWGPRPRRY) from the first N-terminal D1 domain of human LAG-3 (lymphocyte activation gene-3).
Specificity :
Recognizes the 30 aa extra-loop of the first N-terminal D1 domain of LAG-3.
Buffer :
Liquid. In PBS containing 50mM Tris-HCl, 1% BSA and 0.02% sodium azide.
Application Summary :
ELISA, WB
Storage :
-20°C
company information
Enzo Life Sciences
5777 Hines Drive
Ann Arbor, MI 48108
info-us@enzolifesciences.
https://www.enzolifesciences.com
1-800-942-0430
headquarters: USA
Enzo Life Sciences, incorporating ALEXIS® Biochemicals and BIOMOL® International, offers a comprehensive panel of innovative life science reagents. Antibodies, enzymes, proteins, small molecule inhibitors, product libraries, and assay kits are available for research in Cancer, Cell Death, Epigenetics, Genomics, Immunology, Neuroscience, Signal Transduction, and Ubiquitin & Proteasomes, Enabling Discovery in Life Science(tm). Visit www.enzolifesciences.com.